BDNNY vs BBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BDNNY · BOLIDEN AB UNSP ADR EACH REPR 2 ORD$84.53 ▼ 6.84%
BBIO · BridgeBio Pharma$76.03 ▼ 2.75%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BDNNY -2.1%
- BBIO +7.1%
Head to head
| Metric | BDNNY | BBIO |
|---|---|---|
| Price | $84.53 | $76.03 |
| Change today | ▼ 6.84% | ▼ 2.75% |
| Market cap | $14.81B | $14.81B |
| Return, 3 months | -29.5% | -6.2% |
| Return, year to date | -21.9% | -0.6% |
| Return, 1 year | +0.6% | +11.6% |
| P/E (TTM) | 7.9 | – |
| P/B | 0.3 | -5.7 |
| P/E percentile vs own 5y | – | 1st |
| Dividend yield | 2.82% | – |
| Revenue growth (YoY, latest qtr) | – | +192.6% |
| Net profit growth (YoY) | – | +67.3% |
| Gross margin | – | 94.3% |
| Operating margin | – | -37.3% |
| Net margin | – | -62.6% |
| Return on equity | – | – |
| Analyst target vs. price | – | +44.7% |
| Analyst buy share | – | 94% |
| RSI (14) | 29 | 55 |
| 30-day volatility | 49.8% | 37.8% |
| Max drawdown, 1 year | -46.3% | -29.8% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BDNNY is the largest of the group by market value.
- BBIO has returned the most over the past year.
- BBIO has been the calmest stock over the last 30 days.